Dr. Julian Schink Promoted to Chief of Gynecologic Oncology at Cancer Treatment Centers of America

Cancer Treatment Centers of America’s Gynecologic Oncology division is now headed by Dr. Julian Schink. Also leading the Gynecologic Oncology and Medical Oncology at Cancer Treatment Centers of America, Dr. Schink is an experienced healthcare practitioner.

Dr. Julian Schink is a board-certified gynecologist with a positive repute throughout the United States. Dr. Schink has over 30 years of experience in the field of oncology, and he will bring a wide array of medical knowledge to Cancer Treatment Centers of America. He specializes in chemotherapy, hormone therapy, surgery, and custom treatment plans for patients.

Before joining Cancer Treatment Centers of America, Dr. Julian Schink served as the Vice President of Improvement and Integration for Spectrum Health. He was also a professor of gynecologic medicine at several universities in the Midwest region. Dr. Schink is currently licensed in Illinois and Michigan, and he is a member of the American College of Obstetricians and Gynecologists.

From his post at Cancer Treatment Centers of America, Dr. Schink will consult cancer specialists and treat patients with medical issues related to gynecologic cancer. He will likely use his medical expertise to treat women with a variety of cancers, including cervical, vaginal, vulvar, uterine, and ovarian. With the support of the top oncologists and medical researchers in the United States, Dr. Schink will also treat patients with gestational trophoblastic diseases. Schink understands that each patient has different needs, so he will work with his colleagues to design and implement individualized treatment plans. To maximize the odds of success, each treatment plan is based around cutting-edge medicinal practices and modern technology.

Dr. Schink is a passionate man who takes his role as a leader of elite doctors seriously. He understands that new ideas and technological breakthroughs can save lives, so he stays updated about medical news and research. Under his leadership, Cancer Treatment Centers of America will treat patients with a variety of modern methods. Some of these methods are robotic surgery, clinical drug trials, and hyperthermic intraperitoneal chemotherapy.

Through robotic surgery, the risk of human errors are significantly reduced. Dr. Schink and his team plan to use the DaVinci Surgical System. Unlike traditional surgery methods, this system use minimal incisions to provide a less invasive form of laparoscopy and open surgery. The DaVinci Surgical System also uses several high-resolution cameras that offer doctors a clear view of targeted areas, so the doctors at Cancer Treatment Centers of America will be able to make informed decisions throughout procedures. This results in less painful surgeries, quicker recoveries, fewer required blood transfusions, and less scarring. People who receive robotic surgeries often return to their normal lifestyles quicker than patients who receive normal surgical operations.

Dr. Schink’s experience with hyperthermic intraperitioneal chemotherapy should give hope to many cancer patients. Hyperthermic intraperitioneal chemotherapy, or HIPEC, is an advanced option for patients with cancer in the abdomen. The HIPEC treatment option does not circulate chemicals throughout the entire body like systemic options. Instead, HIPEC targets the affected area in the abdomen with the treatment solution. This allows for a stronger concentration of the solution, so a more aggressive approach is permitted without compromising the safety of the patient. The solution may also be heated to help the cancer cells quickly absorb the solution.

Under Dr. Schink’s leadership, the Gynecologic Oncology division will use the experience and research of the National Gynecologic Tumor Board. This panel of oncology professionals will give Cancer Treatment Centers of America access to the case studies and research of medical professionals across the country. If a new breakthrough is discovered via the National Gynecologic Tumor Board, Dr. Schink and his team will know about it. Dr. Schink and his resources are boons for patients.

Leave a Reply

Your email address will not be published. Required fields are marked *